Safety and ARIA Analyses of Oral Anti-amyloid Oligomer Agent Valiltramiprosate in APOE4/4 Homozygotes with Early Alzheimer’s Disease (AD): Results of the Phase 3 78-week APOLLOE4 Trial

valiltramiprosate (ALZ-801) - Alzheon

https://www.aan.com/msa/Public/Events/AbstractDetails/61501

Earvin Liang1; Sharon Cohen2; Marwan Sabbagh3; David Watson4; Susan Abushakra1; Jerome Barakos5; J Patrick Kesslak1; Emer MacSweeney6; Karim Bennys7; Merce Boada8; Rosalind McLaine9; Susan Flint10; Aidan Power10; John A Hey1; Martin Tolar10

Mar 6, 2026